28096-32-4

Upstream product

• 1493-01-2 fluorodiiodomethane 
• 603-35-0 triphenylphosphine 
• 373-52-4 bromofluoromethane 
• 373-53-5 fluoroiodomethane 
• 261504-23-8 [18F]fluoromethyl iodide 

Downstream Products

• 55904-27-3 (E)-(2-fluoro-1-trifluoromethylvinyl)benzene 
• 55904-30-8 1-Fluor-2-pentafluorphenylethen 
• 55904-31-9 1-Fluor-2-pentafluorphenylethen 
• 351-78-0 β-fluorostyrene 
• 1081551-52-1 m-Chlorstyrylfluorid 
• 28028-93-5 m-Trifluormethyl-styrylfluorid 
• 390-75-0 2-fluoro-1,1-diphenylethene 

Relevant academic research and scientific papers

Synthesis and Properties of the Fluoromethylating Agent (Fluoromethyl)triphenylphosphonium Iodide

(Fluoromethyl)triphenylphosphonium iodide has been prepared in a simple and high yield synthesis. The salt was characterized by vibrational, NMR spectroscopy and a single-crystal X-ray structure analysis. The salt crystallizes in an orthorhombic space gro

Visible-Light-Induced Selective Photolysis of Phosphonium Iodide Salts for Monofluoromethylations

The sigma (σ)-hole effect has emerged as a promising tool to construct novel architectures endowed with new properties. A simple yet effective strategy for the generation of monofluoromethyl radicals is a continuing challenge within the synthetic communit

2-Position-selective C[sbnd]H fluoromethylation of six-membered heteroaryl N-oxides with (fluoromethyl)triphenylphosphonium iodide

A mild and efficient method for the regioselective C[sbnd]H fluoromethylation of heteroaryl N-oxides with (fluoromethyl)triphenylphosphonium iodide is presented. With LiOt-Bu as the base and DMSO as the solvent, this reaction delivers a series of C2-fluor

Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid

The present invention relates to novel modified fatty acid analogs, where a positron or gamma-emitting label is placed at a position on a fatty acid backbone and an organic substituent is substituted at the 2,3; 3,4; 4,5; 5,6 and other sequence positions of a fatty acid backbone. These novel fatty acid analogs are designed to enter the tissues of interest by the same long chain fatty acid carrier mechanism as natural fatty acids, however, functional substituents in the 2,3; 3,4; 4,5; 5,6 and other sequence positions, block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest.